FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
ApoGraft aims to solve Bone Marrow Transplantation (BMT) and other transplant rejection associated diseases
Cellect's CEO, Dr. Shai Yarkoni commented "We may provide the answer to a great unmet clinical need causing severe morbidity and death in t... Regenerative Medicine, FDA Cellect Biotechnology, ApoGraft, graft versus host disease, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Bone Marrow Transplant | Grants | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants